Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Banking & Insurance

Executive Exodus at Bridgewater Bancshares Raises Investor Concerns

Andreas Sommer by Andreas Sommer
November 28, 2025
in Banking & Insurance, Dividends, Insider Trading
0
Bridgewater Bancshares Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

A significant divergence is emerging at Bridgewater Bancshares, where attractive yields on preferred shares contrast sharply with a wave of insider selling activity. This trend has placed the financial institution under intense market scrutiny as leadership appears to be reducing their stakes.

Leadership Liquidates Holdings

Recent regulatory filings reveal a notable transaction by Mary Jayne Crocker, Executive Vice President and Chief Strategy Officer. On November 10, she disposed of 8,957 common shares at $16.75 per share, generating $150,029 in proceeds. Following this sale, her direct holdings now stand at 203,105 shares.

The broader picture over the past twelve months presents an even starker contrast: while corporate insiders purchased securities worth $531,400, they simultaneously offloaded holdings valued at a substantial $4.22 million. This nearly 4:1 ratio of sales to purchases suggests diminishing confidence among the company’s leadership in their own stock’s prospects.

Quarterly Performance Falls Short

The company’s financial results for the third quarter of 2025, released on October 21, failed to meet market expectations. Bridgewater reported net earnings of $11.6 million, translating to $0.38 per share, which fell short of the projected $0.40 per share consensus estimate. Revenue figures also disappointed, coming in at $36.2 million against anticipated revenue of $36.8 million.

Should investors sell immediately? Or is it worth buying Bridgewater Bancshares?

Despite these shortcomings, Piper Sandler maintains its “Overweight” rating on the stock with a confirmed price target of $21.00. The investment bank characterizes the stock’s 326 basis points of underperformance as “unwarranted,” attributing the minor weaknesses to increased operational costs associated with recent hiring initiatives.

Strategic Appointment Aims to Bolster Confidence

In response to market conditions, the banking subsidiary announced a strategic personnel move on Monday. Jeff Bajek has been appointed as Senior Vice President and Senior Credit Officer, a decision that underscores the company’s intensified focus on enhanced credit management within a challenging economic landscape.

Key Market Data:
* Common shares closed Wednesday at $17.52
* Preferred shares yield exceeds 7.5%
* Quarterly profit: $11.6 million ($0.38 per share)
* Analyst price target: $21.00 from Piper Sandler

As Bridgewater Bancshares navigates this complex period, investors face a critical question: can the stock regain market confidence despite the dual headwinds of insider divestment and missed quarterly targets? The coming trading sessions will determine whether fundamental valuation metrics or the lack of conviction from company leadership will ultimately drive share price performance.

Ad

Bridgewater Bancshares Stock: Buy or Sell?! New Bridgewater Bancshares Analysis from March 25 delivers the answer:

The latest Bridgewater Bancshares figures speak for themselves: Urgent action needed for Bridgewater Bancshares investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Bridgewater Bancshares: Buy or sell? Read more here...

Tags: Bridgewater Bancshares
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Realty Income Stock
Bonds

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
Unitedhealth Stock
AI & Quantum Computing

UnitedHealth Bets on Artificial Intelligence to Counteract Mounting Pressures

March 25, 2026
Applovin Stock
Analysis

A Tale of Two Signals: AppLovin’s Bullish Analysts and Bearish Insiders

March 25, 2026
Next Post
Newmont Mining Stock

Newmont Shares Surge as Major Investors Pile In

Qualcomm Stock

Qualcomm Gains Momentum with Regulatory Win and Product Launch

MP Materials Stock

MP Materials Stock: A Strategic Shift Gains Momentum

Recommended

BigBearai Holdings Stock

BigBear.ai Faces Critical Test as Revenue Plummets and Losses Mount

6 months ago
D-Wave Quantum Stock

D-Wave Quantum: CFO’s Multi-Million Dollar Exit Amidst Major Capital Raise

4 months ago
Brightcove Stock

Bending Spoons Forges AI-Powered Streaming Future with Brightcove at the Core

6 months ago
Microsoft Stock

Microsoft Faces Critical Earnings Test Amid AI Expectations

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

Trending

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

by SiterGedge
March 25, 2026
0

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant...

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com